Citations

Clear

4610 citation(s) found for "Lu, Brian".

High-Volume, High-Acuity, and High-Impact Learning: Tips and Tricks for Infectious Diseases Training Programs
Luther, Vera , Schultz, Sara , Aziz, Mariam, Balba, Gayle , McCarty, Todd P , Reece, Rebecca , Shnekendorf, Rachel, Sundareshan, Vidya, Chirch, Lisa M , Abdoler, Emily , Acharya, Kartikey, Bartash, Rachel , Blyth, Dana M , Casańas, Beata, Chow, Brian , Clough, Lisa , Cutrell, James B , Doshi, Saumil, Sanctis, Jorgelina de, Faulhaber, Jason, Fiske, Christina T. , Graber, Christopher J. , Johnson, Leonard B., Kwon, Taesung, Lastinger, Allison , Lee, Mi-Kyung , Leuck, Anne‐Marie , Lichtenberger, Paola , Gil, Raul Macias , Mattar, Caline , Matt, Brionna, Maziarz, Eileen K , Melia, Michael T. , Lora, Alfredo J Mena , Miko, Benjamin A. , Mitra, Subhashis , Nematollahi, Saman , Osorio, Georgina, Perez, Frederico , Phadke, Varun K. , Prakash, Katya , Reid, Gail, Riedel, David J. , Rojas‐Moreno, Christian , Salas, Natalie Mariam , Schlaffer, Kathryn, Sobhanie, Mohammad Mahdee , Solomon, Daniel A. , Vikram, Holenarasipur R. , Weber, Devin , Wooten, Darcy , Zerbe, Christa S. , McCarty, T P , Luther, Vera P , Vikram, Holenarasipur R. , Paras, Molly L , Razonable, Raymund R. , Azar, Marwan M. , Blumberg, Emily A. , Butt, Saira , Dare, Ryan K , Dobrzynski, David , Hazra, Aniruddha , Kaltsas, Anna , Kulkarni, Prathit A. , Marcos, Luis A. , Okeke, Nwora Lance , Stapleton, Ann E. , Streit, Judy A. , Thompson, George R , Schooneveld, Trevor Van , Velagapudi, Manasa , Weisenberg, Scott A.

Mayo Clinic

Open Forum Infectious Diseases | January 8, 2024 | Volume: 11 | Issue: 3 | Pages: No page available

10.1093/ofid/ofae016 | PMID 38434609 Get It

Abstract The Infectious Diseases Society of America Training Program Directors Committee met in October 2022 and discussed an observed increase in clinical volume and acuity on infectious diseases (ID) services, and its impact on fellow education. Committee members sought to develop specific goals and strategies related to improving training program culture, preserving quality education on inpatient consult services and in the clinic, and negotiating change at the annual IDWeek Training Program Director meeting. This paper outlines a presentation of ideas brought forth at the meeting and is meant to serve as a reference document for infectious diseases training program directors seeking guidance in this area.
Trends in the Utilization of Surgical Modalities for the Treatment of Drug-Resistant Epilepsy: A Comprehensive 10-Year Analysis Using the National Inpatient Sample
Ghaith, Abdul Karim , El-Hajj, Victor Gabriel , Sánchez-Garavito, Jesús E. , Zamanian, Cameron , Bon‐Nieves, Antonio , Drees, Cornelia , Miller, David A. , Parker, Jonathon J. , Elmi‐Terander, Adrian , Tatum, William O. , Middlebrooks, Erik H. , Bydon, Mohamad , Ghanem, Marc , Bon-Nieves, Antonio, Chen, Baibing , Drees, Cornelia N, Elmi-Terander, Adrian , Van Gompel, Jamie J , Lundstrom, Brian Nils , Grewal, Sanjeet , Middlebrooks, Erik H , Ghaith, Abdul Karim , El-Hajj, Victor Gabriel , Bon-Nieves, Antonio A , Drees, Cornelia , Almeida, João Paulo , Gompel, Jamie J. Van , Lundstrom, Brian N. , Grewal, Sanjeet S.

Mayo Clinic

Neurosurgery | January 8, 2024 | Volume: 94 | Issue: 6 | Pages: 1191-1200

10.1227/neu.0000000000002811 | PMID 38189460 Get It

BACKGROUND AND OBJECTIVES: Epilepsy is considered one of the most prevalent and severe chronic neurological disorders worldwide. Our study aims to analyze the national trends in different treatment modalities for individuals with drug-resistant epilepsy and investigate the outcomes associated with these procedural trends in the United States. METHODS: Using the National Inpatient Sample database from 2010 to 2020, patients with drug-resistant focal epilepsy who underwent laser interstitial thermal therapy (LITT), open surgical resection, vagus nerve stimulation (VNS), or responsive neurostimulation (RNS) were identified. Trend analysis was performed using piecewise joinpoint regression. Propensity score matching was used to compare outcomes between 10 years prepandemic before 2020 and the first peak of the COVID-19 pandemic. RESULTS: This study analyzed a total of 33 969 patients with a diagnosis of drug-resistant epilepsy, with 3343 patients receiving surgical resection (78%), VNS (8.21%), RNS (8%), and LITT (6%). Between 2010 and 2020, there was an increase in the use of invasive electroencephalography monitoring for seizure zone localization ( P = .003). There was an increase in the use of LITT and RNS ( P < .001), while the use of surgical resection and VNS decreased over time ( P < .001). Most of these patients (89%) were treated during the pre-COVID pandemic era (2010-2019), while a minority (11%) underwent treatment during the COVID pandemic (2020). After propensity score matching, the rate of pulmonary complications, postprocedural hematoma formation, and mortality were slightly higher during the pandemic compared with the prepandemic period ( P = .045, P = .033, and P = .026, respectively). CONCLUSION: This study indicates a relative decrease in the use of surgical resections, as a treatment for drug-resistant focal epilepsy. By contrast, newer, minimally invasive surgical approaches including LITT and RNS showed gradual increases in usage.
Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma
Gottlich, Harrison C., Pessoa, Rodrigo Rodrigues , Mahmoud, Ahmed , Garg, I. D. , Orme, Jacob J. , Costello, Brian A. , Cheville, John C. , Mahmoud, Ahmed M , Nabavizadeh, Reza , Dumbravă, Mihai , Garg, Ishita, Lucien, Fabrice

Mayo Clinic

Kidney Cancer | December 29, 2023 | Volume: 7 | Issue: 1 | Pages: 161-172

10.3233/kca-230012 Get It

Background: Approximately 30% of renal cell carcinoma (RCC) cases present with de novo metastatic disease, while 20% to 30% of those with localized disease will develop metastases following surgical resection. Various drug classes have been investigated to treat RCC, including cytokine-based therapies, small molecule Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors (TKIs) and antibody-based therapies. Up to 58% of patients fail to respond to primary immune checkpoint inhibitor (ICI) therapy, and nearly all initial responders experience disease progression due to the development of secondary resistance. Consequently, novel treatment options are being investigated. Objective: Review the rapidly evolving ADC therapeutic landscape in metastatic RCC including recent trials, emerging ADCs targets, and future directions for ADCs in the treatment of advanced RCC. Methods: Literature review using the MEDLINE database on important trials and presentations from the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) conferences. Key words used included “renal cell carcinoma,” “RCC,” “metastatic RCC,” “advanced RCC,” “antibody-based therapies,” “immunotherapy,” “clinical trials,” and “emerging drugs.” Specifically for review of ADCs in RCC, the following search string was used with additional review of bibliographies from retrieved papers: “((antibody drug conjugate) OR (antibody-dependent cellular cytotoxicity) OR (chimeric antigen receptor)) AND ((kidney cancer) OR (renal cell carcinoma))”. Results: Several promising targets including MMP14, EGFR, MCT4, CA9, MET, CDH13, B7-H3, and PSMA were identified with relevant preclinical and clinical studies reviewed. Conclusions: While ADCs therapeutics have not shown benefit to date for renal cell carcinoma, there are ample promising candidates and targets for future research.
Artificial Intelligence Evaluation of Stool Quality Guides Management of Hepatic Encephalopathy Using a Smartphone App
Fagan, Andrew , Gallagher, Mary Leslie, Mousel, Travis, Davis, Brian , Puri, Puneet, Anstey, Jacob, Tiede, David, Kraus, Asaf, Bajaj, Jasmohan S. , Bajaj, Jasmohan S , Fuchs, Michael A. , Puri, Puneet, Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | December 28, 2023 | Volume: 119 | Issue: 5 | Pages: 977-981

10.14309/ajg.0000000000002646 | PMID 38153339 Get It

Lactulose-based hepatic encephalopathy treatment requires bowel movements/day titration, which is improved with Bristol stool scale (BSS) incorporation. Dieta app evaluates artificial intelligence (AI)-based BSS (AI-BSS) with stool images. Initially, controls (N = 13) and cirrhosis patients on lactulose/not on lactulose (n = 33) were trained on the app. They entered self-reported BSS (self-BSS) with AI-BSS communicated. Lactulose dose changes were tracked. A subset (n = 12) was retested with AI communication blocked. Most subjects were comfortable with the app. Self/AI-BSS and lactulose dose/AI-BSS correlation increased with app use. AI-BSS communications improved insight into self-BSS over time. Dieta app to gauge stool AI characteristics was acceptable and increased insight into lactulose dose and BSS in cirrhosis.
How the United States syphilis epidemic may portend a resurgence of an unusual hematologic condition: The connection between syphilis and paroxysmal cold hemoglobinuria
Jacobs, Jeremy W. , Booth, Garrett S. , Adkins, Brian D. , Adkins, Brian David , Jacobs, Jeremy W , Booth, Garrett , Woo, Jennifer S. , Stephens, Laura D.

Mayo Clinic

American Journal of Hematology | December 28, 2023 | Volume: 99 | Issue: 3 | Pages: 484-485

10.1002/ajh.27190 | PMID 38151909 Get It

Challenges in recognising paroxysmal cold hemoglobinuria
Jacobs, Jeremy W. , Booth, Garrett S. , Villalba, Cristina A. Figueroa , Adkins, Brian D. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Woo, Jennifer S. , Stephens, Laura D.

Mayo Clinic

Transfusion Medicine | December 28, 2023 | Volume: 34 | Issue: 1 | Pages: 71-73

10.1111/tme.13024 | PMID 38151804 Get It

Discrepancies among studies reporting the prevalence of positive direct antiglobulin tests in the COVID‐19 patient population
Jacobs, Jeremy W. , Adkins, Brian D. , Booth, Garrett S. , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura D. , Woo, Jennifer S.

Mayo Clinic

Transfusion Medicine | December 28, 2023 | Volume: 34 | Issue: 3 | Pages: 234-235

10.1111/tme.13023 | PMID 38151773 Get It

Functional variations in gamma‐secretase processing of APP are critical determinants of the clinical, biomarker, and cognitive progression of autosomal dominant Alzheimer’s disease
Fitzpatrick, Colleen , Levin, Raina, Shirzadi, Zahra , Chen, Charles D., Farlow, Martin R. , Perrin, Richard J. , Johnson, Keith A. , Chhatwal, Jasmeer P. , Investigators, the Dominantly Inherited Alzheimer Network, Schultz, Stephanie A. , Liu, Lei , Schultz, Aaron P. , Bellier, Jean‐Pierre , Joseph‐Mathurin, Nelly , Benzinger, Tammie L.S. , Day, Gregory S. , Hassenstab, Jason , Jack, Clifford R. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Schofield, Peter William , Karch, Celeste M. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sperling, Reisa Anne , Selkoe, Dennis J. , Investigators, the Dominantly Inherited Alzheimer Network

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S24 | Pages: No page available

10.1002/alz.082318 Get It

AbstractBackgroundThe balance between production, clearance, and toxicity of Ab peptides is central to AD pathobiology. Though highly variable in terms of age of symptom onset (AAO), hundreds of pathogenic variants in Presenilin‐1 (PSEN1) cause autosomal dominant forms of AD (ADAD). PSEN1 forms the catalytic core of the γ‐secretase complex and thereby directly mediates the production of longer, aggregation‐prone Aβ peptides relative to shorter, non‐aggregating peptides. We hypothesized that the broad AAO and biomarker heterogeneity seen across ADAD would be predictable based on mutation‐specific differences in γ‐secretase function, as measured by a ratio of production of shorter vs. longer Aβ species.MethodsAβ‐37, 38, 40, 42, and 43 production was quantified from 162 unique PSEN1 variants expressed in HEK293 cells engineered to lack endogenous wild‐type PSEN1/2 (Figure 1). Prediction of AAO was carried out in 107 PSEN1 variants (characterized by Liu et al, 2022) and then replicated with a set 55 unique PSEN1 variants represented in the Dominantly Inherited Alzheimer Network (DIAN; n = 190 corresponding variant carriers with detailed cognitive and biomarker data; Figure 2).ResultsMutation‐level variations in Aβ production, including a novel composite representing γ‐secretase function (lower score = less g‐processivity), from the cellular model were highly predictive of actual AAO across the 162 mutants examined (Non‐DIAN variants [N = 107]: r = 0.71, p <2.2e‐16; DIAN variants [N = 55]: r = 0.61, p = 6.10e‐07). Our cell‐based γ‐secretase function composite was strongly associated with cerebral PiB‐PET β‐amyloid burden (B[SE] = ‐0.03[0.01], p = 4.06e‐07), MRI gray matter volume (B[SE] = 44.22[6.4], p = 5.15e‐01), cerebrospinal fluid Aβ42/40 (B[SE] = 6.3e‐04[1.5e‐04], p = 4.46e‐05) and phosphorylated tau‐217 (B[SE] = ‐0.01[0.002], p = 1.98e‐05), Clinical Dementia Rating®‐ Sum of Boxes (B[SE] = ‐0.07[0.02], p = 4.86e‐05), and Mini‐Mental State Exam (B[SE] = 0.11[.03], p = 2.17e‐04).ConclusionsBiochemical variations in γ‐secretase function across PSEN1 pathogenic variants broadly predicted the cross‐sectional clinical, cognitive, and biomarker course of ADAD, including AAO. These findings elucidate the critical link between γ‐secretase function, Aβ production, and severity of AD. The novel approach designed here also represents a tool to account for heterogeneity in ADAD clinical trials and to assess the pathogenicity of PSEN1 variants of unknown significance or with limited family history.
Changes in cortical thickness along the Alzheimer disease continuum in people with Down syndrome
Kennedy, James Tyler, Dincer, Aylin , Thippabhotla, Sharmila, Roman, June, Boerwinkle, Anna H. , Chen, Charles D., Price, Julie C. , Sathishkumar, Mithra , McMillan, Liv , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Silverman, Wayne , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Mapstone, Mark , Christian, Bradley T. , Network, Dominantly Inherited Alzheimer, Wisch, Julie K. , Gordon, Brian A. , Flores, Shaney , Benzinger, Tammie L.S. , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Yassa, Michael A. , Brickman, Adam M. , Lao, Patrick , Hartley, Sigan L. , Zaman, Shahid H. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Goate, Alison , Day, Gregory S. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Karch, Celeste M. , Hassenstab, Jason , McDade, Eric , Bateman, Randall J. , Handen, Benjamin L. , Head, Elizabeth , Ances, Beau M. , Schofield, Peter R.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S17 | Pages: No page available

10.1002/alz.079932 Get It

AbstractBackgroundTriplication of the APP allele in Down syndrome (DS) leads to excess amyloid production and Alzheimer’s disease (AD) related cognitive decline. Key biomarkers (amyloid, tau, neurodegeneration) can identify pathological processes that occur before clinical symptoms and more precisely stage adults with DS along the AD continuum. Previous research has used changes in cortical thickness (CT) as an indicator of neurodegeneration in autosomal‐dominant AD1, but not DS‐related AD. It is unclear when and where cortical thinning occurs along the AD continuum in DS and if these differences are associated with increasing AD pathology.MethodCross‐sectional analysis compared DS participants from the Alzheimer Biomarkers Consortium‐Down Syndrome (106 amyloid‐/cognitively unimpaired, nonclinical, 20% reserved for receiver‐operating characteristic, ROC, analyses; 45 amyloid+/cognitively unimpaired, preclinical; 27 amyloid+/cognitively impaired, clinical) who had amyloid positron emission tomography and magnetic resonance imaging (MRI). Amyloid positivity was defined using standardized uptake value ratio (partial volume corrected) cortical mean values (1.42/1.19 for PIB/AV452) and impairment was based on consensus diagnosis. CT differences between nonclinical and clinical groups were calculated in FreeSurfer v5.3 for multiple thresholds (p<.05/.01/.005/.001/.0005/.0001) using a cluster‐wise false discovery rate of .001, corrected across hemispheres, after controlling for age and sex. CT values were extracted for each threshold and used in ROC analyses (nonclinical reserved participants compared against preclinical and preclinical compared against clinical) to identify key cortical regions that best discriminated amyloid positivity and between unimpaired and impaired.ResultSignificant decreases in parietal and inferior temporal CT were observed between nonclinical and clinical (Figures 1 and 2). ROC analyses identified regions in the left (threshold .05) and right (threshold .005) hemispheres that best differentiated nonclinical from preclinical. Observed area under the curves (AUCs) of .772 and .830 exceeded those previously reported for autosomal‐dominant AD (.547/.540)1. Analyses differentiating preclinical from clinical observed AUCs of .786 for left (threshold .0005) and .770 for right (threshold .0005) hemispheres.ConclusionCT differences primarily within posterior cortical regions differentiated adults with DS by amyloid status and cognitive impairment. CT differences were more diffuse for amyloid positivity but more focal for impairment.1. Dincer (2020). NeuroImage: Clinical, 28, 102491.2. Su (2019). Alzheimer’s Dement, 11, 180‐190.
Cross‐sectional comparison of the role of tau burden among Down Syndrome Alzheimer disease and autosomal‐dominant Alzheimer disease
Boerwinkle, Anna H. , Henson, Rachel L. , Thippabhotla, Sharmila, Kennedy, James Tyler, Butt, Omar H. , Chen, Charles D., Christian, Bradley T. , Mapstone, Mark , Tudorascu, Dana , Cohen, Annie , Fagan, Anne M. , Price, Julie C. , Schupf, Nicole , Laymon, Charles M. , Krinsky‐McHale, Sharon J. , Lai, Florence , Rosas, H. Diana , Lott, Ira T. , Silverman, Wayne , Chhatwal, Jasmeer P. , Chui, Helena C., Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Wisch, Julie K. , Gordon, Brian A. , Flores, Shaney , McKay, Nicole S. , Handen, Benjamin L. , Head, Elizabeth , Zammit, Matthew D. , Johnson, Sterling C. , Klunk, William E. , Rafii, Michael S. , O’Bryant, Sid E. , Yassa, Michael A. , Keator, David B. , Hartley, Sigan L. , Zaman, Shahid H. , Lao, Patrick , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Jucker, Mathias , Lee, Jae‐Hong , Xiong, Chengjie , Martins, Ralph N. , Sánchez‐Valle, Raquel , Schofield, Peter William , Xiong, Chengjie , Schindler, Suzanne E. , Morris, John C. , Karch, Celeste M. , Hassenstab, Jason , Benzinger, Tammie L.S. , McDade, Eric , Bateman, Randall J. , Ances, Beau M.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S14 | Pages: No page available

10.1002/alz.079102 Get It

AbstractBackgroundAdults with Down Syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia as they age. This is attributed to triplication of the amyloid precursor protein gene. Recent work demonstrated that amyloid is elevated in DS and accumulates in a similar topography to autosomal dominant AD (ADAD). Tau accumulation is the second hallmark of AD and may be measured using tau positron emission tomography (PET) imaging. The pattern of tau accumulation remains unknown in DS.MethodIn a cross‐sectional analysis we evaluated amyloid and tau positron emission tomography (PET) in 124 participants with DS (109 cognitively stable, 8 symptomatic, 7 no consensus), 29 ADAD mutation carriers (26 asymptomatic, 3 symptomatic), and 201 cognitively normal non‐mutation carriers (CN). Regional cortical standard uptake value ratios (SUVR) for tau imaging were obtained and compared by cognitive status. Similarly, regional cortical amyloid SUVR were obtained and converted to centiloids. We then compared the magnitude of tau burden as well as spatial spread of tau across groups relative to amyloid burden.ResultCompared to CN, tau PET binding was elevated in participants with (µDS = 2.12 ± 0.22 SUVR, µADAD = 2.52 ± 0.37 SUVR) and without (µDS = 1.24 ± 0.15 SUVR, µADAD = 1.16 ± 0.19 SUVR) cognitive changes. For both groups, tau increased with increasing amyloid (centiloids). In some regions, DS had greater tau burden for a given amyloid level (centiloids) (Figure 1). There was increased spatial distribution of tau throughout the brain for participants with DS compared to CN. In contrast, tau burden was more focal in participants with ADAD with tau primarily elevated in posterior regions (Figure 2).ConclusionWhile tau burden was higher with symptomatic disease for both groups, significant differences existed in the overall amount and spatial spread. Tau spread was greatest in participants with DS and more diffuse compared to ADAD. These results indicate a substantial tau burden is present in DS, and suggest not only anti‐amyloid but also tau‐reducing agents should be considered for treating cognitive decline in adults with DS.